PL2907813T3 - Przeciwbakteryjne kompozycje farmaceutyczne - Google Patents

Przeciwbakteryjne kompozycje farmaceutyczne

Info

Publication number
PL2907813T3
PL2907813T3 PL14197877.5T PL14197877T PL2907813T3 PL 2907813 T3 PL2907813 T3 PL 2907813T3 PL 14197877 T PL14197877 T PL 14197877T PL 2907813 T3 PL2907813 T3 PL 2907813T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
antibacterial pharmaceutical
antibacterial
compositions
pharmaceutical
Prior art date
Application number
PL14197877.5T
Other languages
English (en)
Inventor
Francis Xavier Wilson
Peter David Johnson
Richard Vickers
Richard Storer
Graham Michael Wynne
Alan Geoffrey Roach
Moor Olivier De
Colin Richard Dorgan
Paul James Davis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2907813T3 publication Critical patent/PL2907813T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL14197877.5T 2008-12-02 2009-12-01 Przeciwbakteryjne kompozycje farmaceutyczne PL2907813T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds

Publications (1)

Publication Number Publication Date
PL2907813T3 true PL2907813T3 (pl) 2016-09-30

Family

ID=40262471

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09795514T PL2373631T3 (pl) 2008-12-02 2009-12-01 Związki przeciwbakteryjne
PL14197877.5T PL2907813T3 (pl) 2008-12-02 2009-12-01 Przeciwbakteryjne kompozycje farmaceutyczne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09795514T PL2373631T3 (pl) 2008-12-02 2009-12-01 Związki przeciwbakteryjne

Country Status (28)

Country Link
US (3) US8975416B2 (pl)
EP (3) EP2373631B1 (pl)
JP (3) JP5665756B2 (pl)
KR (1) KR101643435B1 (pl)
CN (1) CN102227411B (pl)
AU (1) AU2009323854B2 (pl)
BR (2) BRPI0922220B8 (pl)
CA (1) CA2744962C (pl)
CY (2) CY1116383T1 (pl)
DK (2) DK2907813T3 (pl)
ES (2) ES2575908T3 (pl)
GB (1) GB0821913D0 (pl)
HK (2) HK1162169A1 (pl)
HR (2) HRP20150518T1 (pl)
HU (1) HUE029151T2 (pl)
IL (1) IL213325A (pl)
LT (1) LT2907813T (pl)
MX (1) MX2011005837A (pl)
NZ (1) NZ593111A (pl)
PL (2) PL2373631T3 (pl)
PT (2) PT2907813T (pl)
RS (1) RS54904B1 (pl)
RU (1) RU2525915C2 (pl)
SG (1) SG171939A1 (pl)
SI (2) SI2373631T1 (pl)
SM (2) SMT201500117B (pl)
WO (1) WO2010063996A2 (pl)
ZA (1) ZA201103751B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
JP5845502B2 (ja) * 2010-06-01 2016-01-20 サミット セラピューティクス ピーエルシー クロストリジウム・ディフィシル関連疾患を治療するための化合物
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN110917220A (zh) 2013-02-04 2020-03-27 赛里斯治疗公司 治疗组合物及其使用方法
EP3904502A3 (en) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions and methods
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
RU2722482C2 (ru) 2013-11-25 2020-06-01 Серес Терапеутикс, Инк. Синергические бактериальные композиции и способы их получения и применения
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
WO2016127102A2 (en) * 2015-02-06 2016-08-11 Ernesto Abel-Santos Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
CN111212655A (zh) 2017-08-14 2020-05-29 赛里斯治疗公司 用于治疗胆汁淤积性疾病的组合物和方法
CN111315736B (zh) * 2017-10-05 2023-07-07 桑多斯股份公司 使用酸加成盐制备雷地尼唑的方法
JP2022542822A (ja) * 2019-07-17 2022-10-07 サミット (オックスフォード) リミティド リジニラゾールの調製方法およびその結晶形態
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
IL308757A (en) * 2021-05-24 2024-01-01 Aimmax Therapeutics Inc Combinations of pristinamycin IA and flupristin in the treatment or prevention of bacterial infections
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
AU2022292554A1 (en) 2021-06-14 2024-01-04 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) * 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (pl) 1974-04-30 1975-11-11
JPS50154250A (pl) 1974-05-31 1975-12-12
JPH03500661A (ja) 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール,ベンゾチアゾールまたはベンズイミダゾールの少なくとも1つの結合によって架橋したビスシクロブタレンのモノマー,オリゴマー及びポリマー
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
GB9108279D0 (en) * 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
AU3696495A (en) * 1994-11-17 1996-06-17 F. Hoffmann-La Roche Ag Antibacterial dibenzimidazole derivatives
CN1164227A (zh) 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158158A (ja) 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な1−(4−アルキルオキシフェニル)イミダゾール化合物
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
AU2002218309A1 (en) 2000-11-27 2002-06-03 Ciba Specialty Chemicals Holding Inc. Substituted 5-aryl and 5-heteroaryl-2-(2-hydroxyphenyl)-2h-benzotriazole derivatives as uv absorbers
MXPA03005298A (es) 2000-12-15 2003-10-06 Vertex Pharma Inhibidores de girasa y usos de los mismos.
FR2819180B1 (fr) 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002228317A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2004001058A2 (en) 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
PL374191A1 (pl) 2002-06-13 2005-10-03 Vertex Pharmaceuticals Incorporated Pochodne kwasu 2-ureido-6-heteroarylo-3H-benzoimidazolo-4-karboksylowego i pokrewne związki jako inhibitory gyrazy i/lub topoizomerazy IV do leczeniazakażeń bakteryjnych
US20050260126A1 (en) * 2002-08-30 2005-11-24 Yukitsuka Kudo Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
EP1558341A4 (en) 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
PT1812440E (pt) 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
US20090069384A1 (en) 2005-01-19 2009-03-12 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
US8691859B2 (en) 2005-08-12 2014-04-08 The United States Of America As Represented By The Secretary Of The Army Broad spectrum antibacterial compounds
EP1948635A1 (en) 2005-11-07 2008-07-30 Vertex Pharmaceuticals Incorporated Benzimidazole derivatives as gyrase inhibitors
KR100744827B1 (ko) 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
WO2008075196A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
NZ595280A (en) 2009-02-27 2013-11-29 Enanta Pharm Inc Hepatitis c virus inhibitors
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
EP2414369B1 (en) 2009-04-02 2015-08-12 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Imidazo[2,1-b][1,3,4]thiadiazole derivatives
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
WO2010138791A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
CA2765534C (en) 2009-06-15 2018-09-18 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
JP5845502B2 (ja) 2010-06-01 2016-01-20 サミット セラピューティクス ピーエルシー クロストリジウム・ディフィシル関連疾患を治療するための化合物

Also Published As

Publication number Publication date
HRP20160597T1 (hr) 2016-09-23
US8975416B2 (en) 2015-03-10
EP2907813B1 (en) 2016-04-27
KR20110093925A (ko) 2011-08-18
SMT201500117B (it) 2015-07-09
AU2009323854A2 (en) 2011-06-30
PT2907813T (pt) 2016-08-05
CN102227411A (zh) 2011-10-26
BRPI0922220A8 (pt) 2018-04-03
CY1116383T1 (el) 2017-02-08
US20160184283A1 (en) 2016-06-30
HK1162169A1 (en) 2012-08-24
ZA201103751B (en) 2014-10-29
CY1117934T1 (el) 2017-05-17
SI2907813T1 (sl) 2016-09-30
PL2373631T3 (pl) 2015-10-30
MX2011005837A (es) 2011-11-18
SI2373631T1 (sl) 2015-08-31
BRPI0922220B1 (pt) 2021-03-09
EP2907813A1 (en) 2015-08-19
SMT201600259B (it) 2016-08-31
SG171939A1 (en) 2011-07-28
AU2009323854B2 (en) 2014-06-26
BRPI0922220A2 (pt) 2015-12-29
ES2537059T3 (es) 2015-06-02
RS54904B1 (sr) 2016-10-31
US20120020950A1 (en) 2012-01-26
HUE029151T2 (hu) 2017-02-28
RU2011127165A (ru) 2013-01-10
WO2010063996A2 (en) 2010-06-10
HRP20150518T1 (hr) 2015-07-17
JP2015078220A (ja) 2015-04-23
BRPI0922220B8 (pt) 2021-05-25
EP2373631A2 (en) 2011-10-12
CA2744962A1 (en) 2010-06-10
IL213325A0 (en) 2011-07-31
HK1208668A1 (zh) 2016-03-11
US9763925B2 (en) 2017-09-19
RU2525915C2 (ru) 2014-08-20
CN102227411B (zh) 2015-10-14
JP5665756B2 (ja) 2015-02-04
DK2373631T3 (en) 2015-05-26
JP2017048217A (ja) 2017-03-09
LT2907813T (lt) 2016-10-10
US9314456B2 (en) 2016-04-19
WO2010063996A3 (en) 2010-12-29
CA2744962C (en) 2017-06-06
EP2373631B1 (en) 2015-02-25
ES2575908T3 (es) 2016-07-04
US20150150861A1 (en) 2015-06-04
BR122020013025B1 (pt) 2021-05-18
IL213325A (en) 2016-02-29
JP2012510458A (ja) 2012-05-10
GB0821913D0 (en) 2009-01-07
AU2009323854A1 (en) 2010-06-10
EP3095783A1 (en) 2016-11-23
DK2907813T3 (en) 2016-07-25
PT2373631E (pt) 2015-06-09
NZ593111A (en) 2013-05-31
KR101643435B1 (ko) 2016-07-27

Similar Documents

Publication Publication Date Title
HK1208668A1 (zh) 抗菌藥物組合物
IL247741A0 (en) pharmaceutical preparations
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0814695D0 (en) Pharmaceutical compositions
IL228817A0 (en) Pharmaceutical compounds
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
PL2323623T3 (pl) Kompozycje farmaceutyczne
EP2222313A4 (en) PHARMACEUTICAL COMPOSITIONS
IL208387A0 (en) Pharmaceutical composition
EP2146695A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0709811D0 (en) Pharmaceutical compositions
GB0707127D0 (en) Pharmaceutical compositions
ZA201006224B (en) Pharmaceutical composition
GB2464200B (en) Pharmaceutical composition
GB0712454D0 (en) Pharmaceutical compositions
IL206487A0 (en) Pharmaceutical compositions
GB0817969D0 (en) Pharmaceutical composition
GB0800659D0 (en) Pharmaceutical Compositions
GB2454923B (en) Pharmaceutical compositions
IL201394A0 (en) Niacin - based pharmaceutical compositions
GB0806283D0 (en) Pharmaceutical compositions
GB0806156D0 (en) Pharmaceutical compositions
GB0802024D0 (en) Pharmaceutical compositions
EP2308842A4 (en) PHARMACEUTICAL COMPOSITIONS
GB2463568B (en) Antibacterial formulations